Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisEric L. Simpson, Ashish Bansal, Laurent Eckert et al.|JAMA Dermatology|2019Cited by 505
Dupilumab in Adults and Adolescents with Eosinophilic EsophagitisEvan S. Dellon, Arsalan Shabbir, Marc E. Rothenberg et al.|New England Journal of Medicine|2022Cited by 452
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic EsophagitisIkuo Hirano, Allen Radin, Evan S. Dellon et al.|Gastroenterology|2019Cited by 448
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of AgeMirna Chehade, Jennifer Maloney, Evan S. Dellon et al.|New England Journal of Medicine|2024Cited by 107
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarc E. Rothenberg, Arsalan Shabbir, Evan S. Dellon et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 100